The Spirometric Efficacy of Once-Daily Dosing With Tiotropium in Stable COPD

A wide spectrum of drugs can sometimes give rise to numerous adverse orofacial manifestations, particularly dry mouth, taste disturbances, oral mucosal ulceration, and/or gingival swelling. There are few relevant randomized double-blind controlled studies in this field, and therefore this paper reviews the data from case reports, small series, and non-peer-reviewed reports of adverse drug reactions affecting the orofacial region (available from a MEDLINE search to April, 2003). The more common and significant adverse orofacial consequences of drug therapy are discussed.

show abstract

“…The most common reported ADR after use of the bronchodilator tiotropium is dry mouth (Casaburi et al, 2000).…”

Section: (J) Bronchodilatorsmentioning

confidence: 99%

Adverse Drug Reactions in the Orofacial Region

Scully

Bagán

2004

Critical Reviews in Oral Biology & Medicine

215

View full text Add to dashboard Cite

show abstract

“…Furthermore, there is a need to understand better what patients perceive as an 'exacerbation. ' Studies vary in their definitions of COPD 'exacerbations' [4][5][6][7][8][9][10][11][12][13][14][15], thus making evaluation and comparison difficult, a problem identified in the GOLD international guidelines for the management of COPD. Indeed, the authors of the GOLD guidelines use the term 'exacerbation' without a clear definition [16].…”

Section: Introductionmentioning

confidence: 99%

Exacerbations of chronic obstructive pulmonary disease — A patients' perspective

Adams

Chavannes

Jones

et al. 2006

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryBackground: Exacerbations are now an important clinical variable for research into, and management of, chronic obstructive pulmonary disease (COPD). Emphasis is usually on reductions in the incidence of exacerbations and their impact on quality of life. For such research to be useful and comparable there needs to be a clearly defined understanding of what is meant by the term 'exacerbation'. The aim of this study was to explore the notion of COPD exacerbations from the viewpoint of patients who had recently suffered an exacerbation. Methods: Using principles from grounded theory we conducted semi-structured, in-depth interviews with 23 volunteers from Denmark, the Netherlands and the UK who were identified as having had a COPD exacerbation. Interviews were recorded locally and translated into English for analysis. Notable themes were identified for each informant and their occurrences compared. Results: Patients' reasons for consulting fell into four categories: 'frightening change'; 'change in sputum colour'; 'gradual deterioration'; and 'opportunistic diagnosis'. Most patients consulted frequently about their COPD, but did not afford their exacerbations the same degree of prominence as healthcare professionals (HCPs). Conclusions: These data provide a new way of thinking about COPD exacerbations, offering a greater understanding and classification of the reasons underlying the decision of COPD patients to consult with HCPs. They suggest that the patient perspective of exacerbations is more complex than previously thought. These findings could be applied to clinical practice and research, facilitating focussed decisions on COPD management.

show abstract

“…5 Interestingly, tiotropium does not suppress cough in patients with COPD, although cough was a outcome measure in this study. 6 It should be noted that other studies evaluating the effects of tiotropium have not measured cough. The reasons for the inconsistent effects of anticholinergic agents in disorders in which mucus production should contribute to cough are not clear.…”

Section: Drugs That Affect Mucociliary Factorsmentioning

confidence: 99%